- Home
- NBTX vs PSFE Comparison
NBTX vs PSFE Comparison
Compare NBTX & PSFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- PSFE
- Stock Information
- Founded
- NBTX 2003
- PSFE 1996
- Country
- NBTX France
- PSFE United Kingdom
- Employees
- NBTX N/A
- PSFE N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- PSFE Business Services
- Sector
- NBTX Health Care
- PSFE Consumer Discretionary
- Exchange
- NBTX Nasdaq
- PSFE Nasdaq
- Market Cap
- NBTX 868.8M
- PSFE 765.0M
- IPO Year
- NBTX 2020
- PSFE N/A
- Fundamental
- Price
- NBTX $21.04
- PSFE $12.75
- Analyst Decision
- NBTX Strong Buy
- PSFE Sell
- Analyst Count
- NBTX 1
- PSFE 4
- Target Price
- NBTX $8.00
- PSFE $17.38
- AVG Volume (30 Days)
- NBTX 112.7K
- PSFE 226.8K
- Earning Date
- NBTX 09-30-2025
- PSFE 11-12-2025
- Dividend Yield
- NBTX N/A
- PSFE N/A
- EPS Growth
- NBTX N/A
- PSFE N/A
- EPS
- NBTX N/A
- PSFE N/A
- Revenue
- NBTX $11,930,711.00
- PSFE $1,676,391,000.00
- Revenue This Year
- NBTX N/A
- PSFE $3.18
- Revenue Next Year
- NBTX $74.67
- PSFE $7.05
- P/E Ratio
- NBTX N/A
- PSFE N/A
- Revenue Growth
- NBTX N/A
- PSFE 0.47
- 52 Week Low
- NBTX $2.76
- PSFE $10.63
- 52 Week High
- NBTX $22.51
- PSFE $26.25
- Technical
- Relative Strength Index (RSI)
- NBTX 71.69
- PSFE 40.65
- Support Level
- NBTX $19.11
- PSFE $12.65
- Resistance Level
- NBTX $22.64
- PSFE $13.56
- Average True Range (ATR)
- NBTX 1.64
- PSFE 0.42
- MACD
- NBTX 0.63
- PSFE -0.08
- Stochastic Oscillator
- NBTX 83.03
- PSFE 7.45
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About PSFE Paysafe Limited
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.